Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
series B
Biotech
Pfizer vet debuts Khartis with sights set on thyroid eye disease
Three years after Robert Hoffman sold XinThera to Gilead, the veteran Pfizer chemist has unveiled his latest venture.
Darren Incorvaia
Aug 13, 2026 9:00am
Vaderis' $152M to fund ph. 3 trial in rare blood vessel disorder
Aug 11, 2026 7:00am
Sanofi-backed Expedition lands $115M for ph. 2 COPD trial
Aug 5, 2026 8:00am
Novo Holdings-backed Claris Bio emerges with $118M
Jul 28, 2026 8:00am
Crystalys mines $130M series B to push gout drug through phase 3
Jul 22, 2026 8:00am
Ethyreal Bio raises $101M, joining biotechs gunning for Tepezza
Jun 10, 2026 9:35am
